ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ADMA Biologics, Inc. on June 12, 2018. The report details the completion of a public offering of common stock pursuant to an existing shelf registration statement (Form S-3, File No. 333-225048).
Key Financial Metrics
- Gross Proceeds: Approximately $40.0 million.
- Shares Sold: 8,368,200 shares of common stock.
- Offering Price: $4.78 per share.
- Net Proceeds: Not explicitly stated; gross proceeds are before underwriting discounts, commissions, and estimated fees.
- Over-Allotment Option: Underwriters hold an option to purchase up to 1,255,230 additional shares at the public offering price, expiring July 8, 2018.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity positions for the reporting period.
Material Changes
The primary material change is the increase in equity capital resulting from the sale of 8,368,200 shares. This transaction was executed with Raymond James & Associates, Inc. as the sole book-running manager, Oppenheimer & Co. Inc. as lead manager, and Chardan Capital Markets, LLC as co-manager.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the completed offering. The filing references a press release (Exhibit 99.1) for further details but does not contain specific forward-looking guidance, risk factors, or contingencies within the text of this 8-K. The company is identified as an emerging growth company.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and commissions.
- Confirm whether the underwriters exercised the over-allotment option for the additional 1,255,230 shares.
- Review the attached press release (Exhibit 99.1) for the intended use of proceeds.
- Check subsequent filings for the impact of this capital raise on the company's cash position and dilution metrics.